THERAPEUTIC STRATEGIES TO ALLEVIATE COGNITIVE IMPAIRMENT FOUND BEFORE AND AFTER THE APPEARANCE OF ALZHEIMER’S PATHOLOGY IN AN ANIMAL MODEL OF DOWN SYNDROME (Q3153524): Difference between revisions
Jump to navigation
Jump to search
(Created claim: summary (P836): DOWN SYNDROME (SD) IS CHARACTERISED BY NUMEROUS NEUROMORPHOLOGICAL AND FUNCTIONAL ANOMALIES PRESENT FROM EARLY STAGES OF DEVELOPMENT LEADING TO INTELLECTUAL DISABILITY. In addition, in the later stages of your life, a COGNITIVO DETERIORY due to the precocious ageing and the development of a pathologic pathologic to the encounter in the disease of alzheimer (EA), including accumulative PEPTID-AMILOIDS (A), hyperphosphorylated PROTEIN TAU OVILLOS,...) |
(Changed label, description and/or aliases in en: translated_label) |
||
| label / en | label / en | ||
THERAPEUTIC STRATEGIES TO ALLEVIATE COGNITIVE IMPAIRMENT FOUND BEFORE AND AFTER THE APPEARANCE OF ALZHEIMER’S PATHOLOGY IN AN ANIMAL MODEL OF DOWN SYNDROME | |||
Revision as of 15:12, 12 October 2021
Project Q3153524 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | THERAPEUTIC STRATEGIES TO ALLEVIATE COGNITIVE IMPAIRMENT FOUND BEFORE AND AFTER THE APPEARANCE OF ALZHEIMER’S PATHOLOGY IN AN ANIMAL MODEL OF DOWN SYNDROME |
Project Q3153524 in Spain |
Statements
37,207.5 Euro
0 references
74,415.0 Euro
0 references
50.0 percent
0 references
30 December 2016
0 references
29 December 2019
0 references
UNIVERSIDAD DE CANTABRIA
0 references
43°27'43.34"N, 3°48'35.89"W
0 references
39075
0 references
EL SINDROME DE DOWN (SD) ESTA CARACTERIZADO POR NUMEROSAS ANOMALIAS NEUROMORFOLOGICAS Y FUNCIONALES PRESENTES DESDE ETAPAS TEMPRANAS DEL DESARROLLO QUE DAN LUGAR A DISCAPACIDAD INTELECTUAL. ADEMAS, EN ETAPAS MAS TARDIAS DE SU VIDA SUFREN UN DETERIORO COGNITIVO DEBIDO AL ENVEJECIMIENTO PRECOZ Y AL DESARROLLO DE UNA PATOLOGIA IDENTICA A LA ENCONTRADA EN LA ENFERMEDAD DE ALZHEIMER (EA), INCLUYENDO ACUMULOS DE PEPTIDOS -AMILOIDES (A), OVILLOS DE LA PROTEINA TAU HIPERFOSFORILADA, NEURODEGENERACION, NEUROINFLAMACION, ALTERACIONES EN NEUROGENESIS Y UN AUMENTO DEL ESTRES OXIDATIVO._x000D_ EL RATON TS65DN (TS) ES EL MODELO DE SINDROME DE DOWN MAS UTILIZADO. ESTE MODELO PRESENTA NUMEROSAS CARACTERISTICAS FENOTIPICAS SIMILARES A LAS ENCONTRADAS EN PERSONAS CON SD. ENTRE ELLAS SE ENCUENTRAN LAS ALTERACIONES TEMPRANAS EN LA MORFOLOGIA Y FUNCION DEL CEREBRO, EL ENVEJECIMIENTO TEMPRANO Y LA APARICION DE DISTINTOS HITOS HISTOPATOLOGICOS ENCONTRADOS EN LA EA (NEURODEGENERACION, HIPERFOSFORILACION DE TAU, INCREMENTOS EN LOS NIVELES DE PEPTIDOS A, NEUROINFLAMACION, ALTERACIONES EN NEUROGENESIS, SINAPTOGENESIS Y ESTRES OXIDATIVO) QUE VAN ACOMPAÑADOS DE DETERIORO COGNITIVO._x000D_ UN ASPECTO IMPORTANTE PARA ABORDAR POSIBLES TRATAMIENTOS DESTINADOS A PALIAR LA DISCAPACIDAD INTELECTUAL DE LAS PERSONAS CON SD, ES LA DIFICULTAD DE DIFERENCIAR ENTRE EL DETERIORO COGNITIVO ORIGINADO DURANTE EL NEURODESARROLLO Y EL QUE APARECE POR EL ENVEJECIMIENTO TEMPRANO Y/O POR LA INSTAURACION DE PATOLOGIA TIPO EA. POR ELLO, UN PRIMER OBJETIVO DE ESTE PROYECTO SERA COMPARAR LAS ALTERACIONES COGNITIVAS QUE APARECEN ANTES DEL DESARROLLO DE ESTOS HITOS HISTOPATOLOGICOS Y DESPUES DE ELLOS EN ANIMALES JOVENES Y DE AVANZADA EDAD E INTENTAR DETERMINAR LOS CORRELATOS NEUROBIOLOGICOS RESPONSABLES DE ESTAS ALTERACIONES._x000D_ EN LOS ULTIMOS AÑOS NUESTRO GRUPO, Y OTROS GRUPOS DE INVESTIGACION, HEMOS IDENTIFICADO APROXIMACIONES TERAPEUTICAS QUE PALIAN LAS ALTERACIONES COGNITIVAS EN LA POBLACION DE RATONES TS JOVENES. ESTOS ESTUDIOS HAN POSIBILIZADO EL DESARROLLO DE ENSAYOS CLINICOS ORIENTADOS A LA MEJORIA DE LA FUNCIONES COGNITIVAS DE PERSONAS JOVENES CON SD. SIN EMBARGO, HASTA LA FECHA LOS RESULTADOS DE LOS ENSAYOS CLINICOS REALIZADOS EN PERSONAS DE MAS AVANZADA EDAD HAN DADO LUGAR, EN SU MAYORIA, A RESULTADOS CONTRADICTORIOS O NEGATIVOS. POR ELLO, UN SEGUNDO OBJETIVO DE ESTE PROYECTO ES EVALUAR CUATRO COMPUESTOS QUE POR SUS DIVERSAS PROPIEDADES NEUROPROTECTORAS PODRIAN MEJORAR LA PERDIDA DE HABILIDADES COGNITIVAS ASOCIADAS AL ENVEJECIMIENTO Y/O A LA PATOLOGIA TIPO EA. LOS COMPUESTOS QUE VAMOS A ESTUDIAR (LA MELATONINA, LA CURCUMINA, ANTICUERPOS CONTRA INTERLEUKINAS Y EL ACIDO LINOLENICO (OMEGA 3)) HAN SIDO ELEGIDOS EN BASE A SUS PROPIEDADES ANTIOXIDANTES, ANTIINFLAMATORIAS, O NEUROPROTECTORAS. AL SER ALGUNOS DE ESTOS COMPUESTOS DE ADMINISTRACION HABITUAL EN PERSONAS SANAS SIN EFECTOS SECUNDARIOS CONOCIDOS, LA OBTENCION DE RESULTADOS POSITIVOS EN RATONES, AGILIZARIA EL DISEÑO Y REALIZACION DE ENSAYOS CLINICOS QUE SERAN EL OBJETIVO DE NUESTRAS FUTURAS INVESTIGACIONES. (Spanish)
0 references
DOWN SYNDROME (SD) IS CHARACTERISED BY NUMEROUS NEUROMORPHOLOGICAL AND FUNCTIONAL ANOMALIES PRESENT FROM EARLY STAGES OF DEVELOPMENT LEADING TO INTELLECTUAL DISABILITY. In addition, in the later stages of your life, a COGNITIVO DETERIORY due to the precocious ageing and the development of a pathologic pathologic to the encounter in the disease of alzheimer (EA), including accumulative PEPTID-AMILOIDS (A), hyperphosphorylated PROTEIN TAU OVILLOS, Neurodegeneration, NEUROINFLAMACION, neurogenesis ALTERATIONS AND an increase of the OXIDATIVE STRES._x000D_ The RATON TS65DN (TS) is the most used model of DOWN SINDROME. THIS MODEL HAS NUMEROUS PHENOTYPIC CHARACTERISTICS SIMILAR TO THOSE FOUND IN PEOPLE WITH SD. Among them are found the temporary alterations in the morphology and functioning of the CEREBRO, the early ageing and the apportionment of different histopatologic hypotheses found in the EA (Neurodegeneration, HIPERPHOSFORILATION OF TAU, INCREMENTS IN THE LEVELS OF PEPTIDS A, NEUROINFLAMACION, ALTERATIONS IN Neurogenesis, Synaptogenesis AND THIS OXIDATIVE) WE WORK THE COGNITIVO DETERIORO DETERIORO DETERIORO COGNITIVO._x000D_ A IMPORTANT ASPECTIVE TO ABOUT POSIBLE TREATMENTS DESTINTED TO THE INTELECTUAL DISACACITY OF PERSONS WITH SD, it IS THE DIFFICULT OF DIFFERENTY BETWEEN THE COGNITIVING DETERIORY originated DURING THE neurodevelopment AND THE WORKING FOR THE TEMPRANE Aging AND/OR THE INFORMATION OF PATOLOGY TYPE EA. For this reason, a first objective of this project will be to buy the COGNITIVE ALTERATIONS that arose before the development of these histomatological histologic HITs and awaited them in young and anticipated animals and to enter into the determination of the neurobiologic correlates responsible for these alterations._x000D_ IN THE ULTIMATE YEARS OUR GROUP, and other research groups, we have identified TERAPEUTIC approximations that palade the COGNITIVE ALTERATIONS in the ST YOUTH RATONES POULATIONS. THESE STUDIES HAVE ENABLED THE DEVELOPMENT OF CLINICAL TRIALS AIMED AT IMPROVING THE COGNITIVE FUNCTIONS OF YOUNG PEOPLE WITH SD. HOWEVER, TO DATE, THE RESULTS OF CLINICAL TRIALS IN OLDER PEOPLE HAVE, FOR THE MOST PART, RESULTED IN CONTRADICTORY OR NEGATIVE RESULTS. THEREFORE, A SECOND OBJECTIVE OF THIS PROJECT IS TO EVALUATE FOUR COMPOUNDS THAT BECAUSE OF THEIR DIFFERENT NEUROPROTECTIVE PROPERTIES COULD IMPROVE THE LOSS OF COGNITIVE SKILLS ASSOCIATED WITH AGING AND/OR PATHOLOGY TYPE EA. THE COMPOUNDS WE ARE GOING TO STUDY (MELATONIN, CURCUMIN, ANTIBODIES AGAINST INTERLEUKINS AND LINOLENIC ACID (OMEGA 3)) HAVE BEEN CHOSEN BASED ON THEIR ANTIOXIDANT, ANTI-INFLAMMATORY, OR NEUROPROTECTIVE PROPERTIES. SINCE SOME OF THESE COMPOUNDS ARE USUALLY ADMINISTERED IN HEALTHY PEOPLE WITHOUT KNOWN SIDE EFFECTS, OBTAINING POSITIVE RESULTS IN MICE, AGILIZARIA THE DESIGN AND CONDUCT OF CLINICAL TRIALS THAT WILL BE THE OBJECTIVE OF OUR FUTURE RESEARCH. (English)
12 October 2021
0 references
Santander
0 references
Identifiers
PSI2016-76194-R
0 references